What is the Best Antimicrobial Treatment for Severe Community-Acquired Pneumonia (Including the Role of Steroids and Statins and Other Immunomodulatory Agents)

• Autores: Oriol Sibila, Marcos I. Restrepo, Antonio Anzueto
• Localización: Infectious disease clinics of North America, ISSN 0891-5520, Vol. 27, Nº. 1, 2013 (Ejemplar dedicado a: Community-Acquired pneumonia: Controversies and questions), págs. 133-147
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the United States. The mortality rate due to severe CAP has shown little improvement over the past few years, with a rate as high as 50% mainly in patients admitted to intensive care units. Death and adverse outcomes from CAP result from a complex interplay between the pathogen and the host. Several therapies have been tested in patients with severe CAP in recent years. This article reviews recent data regarding different treatments including antimicrobials and adjunctive therapies in patients with severe CAP.